We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+24.89%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,007.9%
AUM
$71.3B
AUM Growth
+$6.48B
(+10%)
Cap. Flow
-$2.43B
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
29.48%
Holding
1,130
New
174
Increased
291
Reduced
392
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Devon Energy
DVN
|
+$353M |
| 2 |
Marvell Technology
MRVL
|
+$150M |
| 3 |
Spyre Therapeutics
SYRE
|
+$126M |
| 4 |
BridgeBio Pharma
BBIO
|
+$116M |
| 5 |
Dover
DOV
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$713M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$355M |
| 3 |
CTRA
Coterra Energy
CTRA
|
+$289M |
| 4 |
Royalty Pharma
RPRX
|
+$259M |
| 5 |
Eli Lilly
LLY
|
+$236M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.29% |
| 2 | Healthcare | 14.03% |
| 3 | Financials | 12.39% |
| 4 | Industrials | 8.94% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTNM
801
Contineum Therapeutics
CTNM
$570M
| $5.38M | 0.01% |
+328,000
| New | +$4.3M |
|
802
Suncor Energy
SU
$80.7B
| $5.37M | 0.01% |
100,000
+10,000
| +11% | +$633K |
|
|
EROC
803
ERock Inc
EROC
$610M
| $5.36M | 0.01% |
+369,484
| New | +$5.88M |
|
804
Box
BOX
$4.73B
| $5.31M | 0.01% |
+200,000
| New | +$4.99M |
|
805
Hertz
HTZ
$738M
| $5.21M | 0.01% |
+2,300,843
| New | +$12.6M |
|
806
Tyra Biosciences
TYRA
$1.31B
| $5.17M | 0.01% |
+162,000
| New | +$5.36M |
|
|
MESH
807
Meshflow Acquisition Corp
MESH
$435M
| $5M | 0.01% |
500,000
| – | – |
|
808
RadNet
RDNT
$5.58B
| $4.94M | 0.01% |
+80,081
| New | +$4.5M |
|
809
Cameco
CCJ
$43.7B
| $4.89M | 0.01% |
+48,000
| New | +$5.38M |
|
810
Warrior Met Coal
HCC
$5.51B
| $4.86M | 0.01% |
59,887
-259,982
| -81% | -$23.5M |
|
|
DYNC
811
Dynamix Corp
DYNC
$241M
| $4.86M | 0.01% |
450,000
-69,086
| -13% | -$742K |
|
812
Tyler Technologies
TYL
$14B
| $4.85M | 0.01% |
16,600
-1,800
| -10% | -$569K |
|
813
AN2 Therapeutics
ANTX
$216M
| $4.84M | 0.01% |
1,000,000
| – | – |
|
814
NET Power
NPWR
$164M
| $4.74M | 0.01% |
2,840,000
+1,300,000
| +84% | +$2.35M |
|
815
Amneal Pharmaceuticals
AMRX
$6.01B
| $4.71M | 0.01% |
+272,000
| New | +$3.73M |
|
|
816
Revolution Medicines Inc Warrant
RVMDW
$129M
| $4.69M | 0.01% |
500,000
| – | – |
|
|
BLRK
817
Bluerock Acquisition Corp
BLRK
$232M
| $4.49M | 0.01% |
450,000
| – | – |
|
|
MMED
818
MiniMed Group Inc
MMED
$6.4B
| $4.49M | 0.01% |
+300,000
| New | +$3.95M |
|
819
Kyverna Therapeutics
KYTX
$472M
| $4.46M | 0.01% |
500,000
| – | – |
|
820
Equillium
EQ
$162M
| $4.45M | 0.01% |
1,390,253
-3,939,163
| -74% | -$9.44M |
|
821
Ameriprise Financial
AMP
$48.7B
| $4.44M | 0.01% |
9,668
-55,100
| -85% | -$25.3M |
|
822
Cullinan Oncology
CGEM
$1.37B
| $4.33M | 0.01% |
+238,000
| New | +$3.53M |
|
823
Owens Corning
OC
$10.2B
| $4.33M | 0.01% |
+27,250
| New | +$3.31M |
|
|
CMPS
824
Compass Pathways
CMPS
$2.1B
| $4.25M | 0.01% |
300,000
| – | – |
|
|
IVA
825
Inventiva
IVA
$1.05B
| $4.23M | 0.01% |
+1,120,000
| New | +$5.38M |
|
Similar funds
Adage Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Adage Capital Partners held 1,130 positions worth $71.3B, up 10% from $64.8B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners withdrew a net $2.43B in Q2 2026, closing 128 positions and reducing 392 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $355M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Marvell Technology worth $222M.
- Adage Capital Partners's largest Q2 2026 buy was Marvell Technology: 745,800 shares worth $222M.
- Adage Capital Partners added most to Devon Energy in Q2 2026, an estimated $353M increase.
- Adage Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $713M.
- Adage Capital Partners fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $355M.
- Adage Capital Partners's ten largest holdings make up 29% of its $71.3B portfolio in Q2 2026.
- Adage Capital Partners opened 174 new positions and closed 128 in Q2 2026.
- Adage Capital Partners's portfolio value rose 10% quarter-over-quarter to $71.3B.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.